As filed with the Securities and Exchange Commission on January 15, 2021

Registration No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

 

HTG MOLECULAR DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

86-0912294

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

3430 E. Global Loop

Tucson, Arizona

 

85706

(Address of Principal Executive Offices)

 

(Zip Code)

 

2014 Employee Stock Purchase Plan

(Full titles of the plans)

John L. Lubniewski

Chief Executive Officer

HTG Molecular Diagnostics, Inc.

3430 E. Global Loop

Tucson, Arizona 85706

(877) 289-2615

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

Steven M. Przesmicki, Esq.

Cooley LLP

4401 Eastgate Mall

San Diego, California 92121

(858) 550-6000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”

 


 

“accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

  

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

 

Title of securities

to be registered

 

Amount

to be

registered (1)

 

Proposed

maximum

offering price

per share (2)

 

Proposed

maximum

aggregate

offering price (2)

 

Amount of

registration fee

2014 Employee Stock Purchase Plan

Common Stock, $0.001 par value per share

 

13,000 (3)

 

$6.12

 

$79,560.00

 

$8.68

 

 

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Common Stock (the “Common Stock”) of HTG Molecular Diagnostics, Inc. (the “Registrant”) that become issuable under the above-referenced plan by reason of any stock dividend, stock split, recapitalization or other similar transaction.

 

(2)

This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on January 11, 2021, as reported on The Nasdaq Capital Market.

 

(3)

Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan (the “2014 ESPP”) on January 1, 2021 pursuant to an “evergreen” provision contained in the 2014 ESPP. Pursuant to such provision, on January 1 of each year from January 1, 2016 through and including January 1, 2024, the number of shares authorized for issuance under the 2014 ESPP is automatically increased by a number equal to the least of: (a) 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; (b) 13,000 shares; and (c) a number determined by the Board that is less than the amounts set forth in the foregoing clauses (a) and (b).

   


 


 

INCORPORATION OF DOCUMENTS BY REFERENCE

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan is effective.

The Registrant previously registered shares of its Common Stock for issuance under the 2014 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 7, 2015 (File No. 333-203930), March 25, 2016 (File No. 333-210401), March 24, 2017 (File No. 333-216942), January 17, 2018 (File No. 333-222571), January 18, 2019 (File No. 333-229303) and January 17, 2020 (File No. 333-235961). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

 

EXHIBIT INDEX

 

 

 

 

Exhibit

Number

  

Description

 

 

  4.1

  

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on May 12, 2015).

 

 

  4.2

  

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on November 19, 2020).

 

 

  4.3

  

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37369), filed with the Commission on May 12, 2015).

 

 

  4.4

  

Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201313), originally filed with the Commission on December 30, 2014, as amended).

 

 

  5.1

  

Opinion of Cooley LLP.

 

 

23.1

  

Consent of BDO USA, LLP.

 

 

23.2

  

Consent of Cooley LLP. Reference is made to Exhibit 5.1.

 

 

24.1

  

Power of Attorney. Reference is made to the signature page hereto.

 

 

 

99.1

 

HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan.

 


 


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tucson, State of Arizona, on January 15, 2021.

 

HTG MOLECULAR DIAGNOSTICS, INC.

 

 

By:

 

/s/ John L. Lubniewski

 

 

John L. Lubniewski

 

 

President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John L. Lubniewski and Shaun D. McMeans, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

 

Date

 

 

 

/s/ John L. Lubniewski

     John L. Lubniewski

  

President, Chief Executive Officer and Member 

of the Board of Directors

(Principal Executive Officer)

 

January 15, 2021

 

 

 

/s/ Shaun D. McMeans

     Shaun D. McMeans

  

Chief Financial Officer

(Principal Financial Officer)

 

January 15, 2021

 

 

 

 

 

/s/ Laura L. Godlewski

 

Vice President of Finance and

 

January 15, 2021

     Laura L. Godlewski

 

Principal Accounting Officer

(Principal Accounting Officer)

 

 

 

 

 

/s/ Ann F. Hanham

Lead Independent Director

 

January 15, 2021

     Ann F. Hanham

 

 

 

 

/s/ Timothy B. Johnson

     Timothy B. Johnson

Executive Chairman of the Board of Directors

January 15, 2021

 

 

 

/s/ Harry A. George

     Harry A. George

  

Member of the Board of Directors

 

January 15, 2021

 

 

 

/s/ Donnie M. Hardison

     Donnie M. Hardison

  

Member of the Board of Directors

 

January 15, 2021

 


 

 

 

 

/s/ James T. LaFrance

     James T. LaFrance

  

Member of the Board of Directors

 

January 15, 2021

 

 

 

 

 

/s/ Lee R. McCracken

     Lee R. McCracken

  

Member of the Board of Directors

 

January 15, 2021

 

 

 

/s/ Michelle R. Griffin

     Michelle R. Griffin

  

Member of the Board of Directors

 

January 15, 2021

 

 

HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more HTG Molecular Diagnostics Charts.
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more HTG Molecular Diagnostics Charts.